This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Data inconcistency in reporting of cardiovascular events in the FOURIER study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Data inconcistency in reporting of cardiovascular events in the FOURIER study

The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, authors of a study (1) observed some inconsistencies between the information in the Clinical Study Report (CSR) and that in the 2017 primary trial results publication.

  • Mortality data in the primary results publication were compared with that in the CSR
    • in cases of discrepancy between the sources, an independent committee blindly readjudicated and restored the cause of death according to the information in the CSR narratives
  • Analysis of the FOURIER Clinical Study Report found the clinical events committee and local clinical investigator differed in recorded cause of death in 41.4% of cases.
    • for 360/870 deaths (41.4%), the cause of death adjudicated by the FOURIER clinical events committee differed from that declared by the local clinical investigator
      • when comparing the CSR information with the 2017 primary results publication, the study authors found 11 more deaths from myocardial infarction in the evolocumab group (36 vs 25) and 3 less deaths in the placebo group (27 vs 30, respectively)
      • in the CSR, the number of deaths due to cardiac failure in the evolocumab group was almost double those in the placebo group (31 vs 16)
      • while cardiac and vascular deaths were not assessed as separate outcomes in the original trial analysis, after readjudication, the study authors noted that cardiac deaths were numerically, but non-significantly, higher in the evolocumab group (113) than in the placebo group (88; relative risk (RR) 1.28, 95% CI 0.97 to 1.69, p=0.078), whereas non-cardiac vascular deaths were similar between groups (37 in each; RR 1.00, 95% CI 0.63 to 1.58, p=0.999)
      • the reported HR for cardiovascular mortality in the original trial analysis was 1.05 (95% CI 0.88 to 1.25); after readjudication, we found a greater (although still non-significant) relative increase in cardiovascular mortality in the evolocumab treatment group (RR 1.20, 95% CI 0.95 to 1.51, p=0.13)

The study authors suggest that:

  • ".. At the time the trial was terminated early, a non-significantly higher risk of cardiovascular mortality was observed with evolocumab, which was numerically greater in our readjudication. A complete restoration of the FOURIER trial data is required. In the meantime, clinicians should be sceptical about prescribing evolocumab for patients with established atherosclerotic cardiovascular disease.."

Notes:

  • The FOURIER trial was planned for 56 months (4.7 years)
    • however, it was terminated early for apparent benefit after a median follow-up of 2.2 years (2)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.